H James Harwood

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Advances in Diabetes Treatment 2005 - Second Annual Conference
    H James Harwood
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Groton Laboratories, CT 06340, USA
    IDrugs 8:374-7. 2005
  2. ncbi Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition
    H James Harwood
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, MS 820 3190, Eastern Point Road, Groton, CT 06340, USA
    Expert Opin Ther Targets 9:267-81. 2005
  3. ncbi Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome
    H James Harwood
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    Curr Opin Investig Drugs 5:283-9. 2004
  4. ncbi Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals
    Julie L Hawkins
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton New London Laboratories, Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 326:801-8. 2008
  5. ncbi Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms
    George Chang
    Departments of Metabolic Diseases and Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Curr Opin Drug Discov Devel 5:562-70. 2002
  6. ncbi CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
    Charles E Chandler
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer, Inc, Eastern Point Road, Groton, CT 06340, USA
    J Lipid Res 44:1887-901. 2003
  7. ncbi A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore
    J Richard Miller
    Pfizer, Inc, Ann Arbor, MI 48105, USA
    Proc Natl Acad Sci U S A 106:1737-42. 2009
  8. ncbi Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2
    Jeffrey W Corbett
    Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 20:2383-8. 2010
  9. ncbi Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase
    H James Harwood
    Departments of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    J Lipid Res 46:547-63. 2005
  10. ncbi Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals
    H James Harwood
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Groton, Connecticut 06340, USA
    J Biol Chem 278:37099-111. 2003

Collaborators

Detail Information

Publications15

  1. ncbi Advances in Diabetes Treatment 2005 - Second Annual Conference
    H James Harwood
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Groton Laboratories, CT 06340, USA
    IDrugs 8:374-7. 2005
  2. ncbi Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition
    H James Harwood
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, MS 820 3190, Eastern Point Road, Groton, CT 06340, USA
    Expert Opin Ther Targets 9:267-81. 2005
    ....
  3. ncbi Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome
    H James Harwood
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    Curr Opin Investig Drugs 5:283-9. 2004
    ....
  4. ncbi Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals
    Julie L Hawkins
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton New London Laboratories, Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 326:801-8. 2008
    ....
  5. ncbi Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms
    George Chang
    Departments of Metabolic Diseases and Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Curr Opin Drug Discov Devel 5:562-70. 2002
    ..Finding a degree of efficacy that can be safely tolerated defines the dilemma surrounding the advancement of these compounds to clinical practice...
  6. ncbi CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
    Charles E Chandler
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer, Inc, Eastern Point Road, Groton, CT 06340, USA
    J Lipid Res 44:1887-901. 2003
    ..Together, these data support further evaluation of CP-346086 in hyperlipidemia...
  7. ncbi A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore
    J Richard Miller
    Pfizer, Inc, Ann Arbor, MI 48105, USA
    Proc Natl Acad Sci U S A 106:1737-42. 2009
    ....
  8. ncbi Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2
    Jeffrey W Corbett
    Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 20:2383-8. 2010
    ..Low nanomolar, non-specific ACC-isozyme inhibitors that exhibited good rat pharmacokinetics were obtained from this chemotype...
  9. ncbi Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase
    H James Harwood
    Departments of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    J Lipid Res 46:547-63. 2005
    ..Dual-action glycogenolysis and cholesterolgenesis inhibitors therefore have the potential to favorably affect both the hyperglycemia and the dyslipidemia of type 2 diabetes...
  10. ncbi Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals
    H James Harwood
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Groton, Connecticut 06340, USA
    J Biol Chem 278:37099-111. 2003
    ..Taken together, These observations indicate that isozyme-nonselective ACC inhibition has the potential to favorably affect risk factors associated with the metabolic syndrome...
  11. ncbi Aminopyrrolidineamide inhibitors of site-1 protease
    Bruce A Hay
    Pfizer Global Research and Development Groton Laboratories, Groton, CT 06340, USA
    Bioorg Med Chem Lett 17:4411-4. 2007
    ..The discovery and efficacy of a series of potent aminopyrrolidineamide-based inhibitors of sterol regulatory element binding protein site-1 protease is described...
  12. ncbi Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors
    Sean Ekins
    Computational Biology, ACT LLC, 601 Runnymede Ave, Jenkintown, PA 19046, USA
    Drug Metab Dispos 35:493-500. 2007
    ..This study has demonstrated the potential for ligand-based computational pharmacophore modeling of human CYP51 and enables a high-throughput screening system for drug discovery and data base mining...
  13. ncbi Partial blockage of sterol biosynthesis with a squalene synthase inhibitor in early postnatal Niemann-Pick type C npcnih null mice brains reduces neuronal cholesterol accumulation, abrogates astrogliosis, but may inhibit myelin maturation
    Patrick C Reid
    Department of Biochemistry, Dartmouth Medical School, Hanover, NH 03755, USA
    J Neurosci Methods 168:15-25. 2008
    ..The methods described in the current work have general applicability for lipid metabolism studies in mice brains in various pathophysiological conditions...
  14. ncbi Acetyl-coenzyme A carboxylases: versatile targets for drug discovery
    Liang Tong
    Department of Biological Sciences, Columbia University, New York, NY 10027, USA
    J Cell Biochem 99:1476-88. 2006
    ..This review summarizes these new progresses and also offers some prospects in terms of the future directions for the studies on these important enzymes...
  15. ncbi Old world nonhuman primate models of type 2 diabetes mellitus
    Janice E Wagner
    Department of Pathology Wake Forest University School of Medicine, Winston-Salem, NC, USA
    ILAR J 47:259-71. 2006
    ..Thus, Old World NHPs are a valuable animal model of type 2 diabetes to study disease progression, associated risk factors, and potential new treatments...